These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29545966)

  • 21. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
    Kruger DT; Alexi X; Opdam M; Schuurman K; Voorwerk L; Sanders J; van der Noort V; Boven E; Zwart W; Linn SC
    Int J Cancer; 2020 Apr; 146(8):2348-2359. PubMed ID: 31490549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
    Morrissey JJ; Raney S
    Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crosstalk between progesterone receptor membrane component 1 and estrogen receptor α promotes breast cancer cell proliferation.
    Pedroza DA; Subramani R; Tiula K; Do A; Rashiraj N; Galvez A; Chatterjee A; Bencomo A; Rivera S; Lakshmanaswamy R
    Lab Invest; 2021 Jun; 101(6):733-744. PubMed ID: 33903732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FEN1 is a prognostic biomarker for ER+ breast cancer and associated with tamoxifen resistance through the ERα/cyclin D1/Rb axis.
    Xu L; Shen JM; Qu JL; Song N; Che XF; Hou KZ; Shi J; Zhao L; Shi S; Liu YP; Qu XJ; Teng YE
    Ann Transl Med; 2021 Feb; 9(3):258. PubMed ID: 33708885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer.
    He YJ; Wu JZ; Ji MH; Ma T; Qiao EQ; Ma R; Tang JH
    Exp Ther Med; 2013 Mar; 5(3):813-818. PubMed ID: 23408138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
    Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA
    Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
    Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
    BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD36 plays a critical role in proliferation, migration and tamoxifen-inhibited growth of ER-positive breast cancer cells.
    Liang Y; Han H; Liu L; Duan Y; Yang X; Ma C; Zhu Y; Han J; Li X; Chen Y
    Oncogenesis; 2018 Dec; 7(12):98. PubMed ID: 30573731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
    Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
    Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of Increased Invasiveness of Breast Cancer Cells With Acquired Tamoxifen Resistance by Suppression of CYR61.
    Bauerschmitz G; Hüchel S; Gallwas J; Gründker C
    Cancer Genomics Proteomics; 2023; 20(6):531-538. PubMed ID: 37889058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
    Li J; Lu M; Jin J; Lu X; Xu T; Jin S
    Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.
    Perez White B; Molloy ME; Zhao H; Zhang Y; Tonetti DA
    Mol Cancer; 2013 May; 12():34. PubMed ID: 23634843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The G-protein-coupled estrogen receptor, a gene co-expressed with ERα in breast tumors, is regulated by estrogen-ERα signalling in ERα positive breast cancer cells.
    Pal U; Manjegowda MC; Singh N; Saikia S; Philip BS; Jyoti Kalita D; Kumar Rai A; Sarma A; Raphael V; Modi D; Chandra Kataki A; Mukund Limaye A
    Gene; 2023 Aug; 877():147548. PubMed ID: 37279863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic and predictive value of low estrogen receptor expression in breast cancer.
    Bouchard-Fortier A; Provencher L; Blanchette C; Diorio C
    Curr Oncol; 2017 Apr; 24(2):e106-e114. PubMed ID: 28490933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.
    Yu-Rice Y; Jin Y; Han B; Qu Y; Johnson J; Watanabe T; Cheng L; Deng N; Tanaka H; Gao B; Liu Z; Sun Z; Bose S; Giuliano AE; Cui X
    Oncogene; 2016 Oct; 35(41):5400-5411. PubMed ID: 27041579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA; Oza BP; Colomer R; Lupu R
    Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Downregulation of CXXC Finger Protein 4 Leads to a Tamoxifen-resistant Phenotype in Breast Cancer Cells Through Activation of the Wnt/β-catenin Pathway.
    Fu Y; Wang Z; Luo C; Wang Y; Wang Y; Zhong X; Zheng H
    Transl Oncol; 2020 Feb; 13(2):423-440. PubMed ID: 31911277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling.
    Badia E; Duchesne MJ; Semlali A; Fuentes M; Giamarchi C; Richard-Foy H; Nicolas JC; Pons M
    Cancer Res; 2000 Aug; 60(15):4130-8. PubMed ID: 10945620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.